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Altered anion handling by choroid plexus in renal insufficiency
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Altered anion handling by choroid plexus in renal insufficiency. Abnor-
mal localization of 99mTc pertechnetate was detected in the choroid
plexus of patients with renal insufficiency despite the administration of
potassium perchiorate. This was found in 8 of 21 studies on patients on
conservative medical treatment, in 35 of 41 studies in patients on
hemodialysis, in 12 of 22 studies in renal transplant recipients, and in 1
of 5 with acute renal insufficiency, but not in any of 33 persons free of
renal disease. Abnormal retention of pertechnetate was also observed
in the salivary glands of 21 renal patients. The increased localization of
99mTc pertechnetate could not be related to high blood levels of
radioactivity, altered protein binding, increased erythrocyte labeling or
to impaired gastrointestinal absorption of potassium perchlorate. It is
proposed that this finding represents a manifestation of choroid plexus
dysfunction resulting in altered handling of anions by this organ. A
possible relation to neurological disease in chronic renal insufficiency is
suggested.
Conservation des anions par les plexus choroldes modifiée lors de
l'insuffisance rénale. Une localisation anormale de pertechnetate de
a été détectée dans les plexus choroides de malades ayant une
insuffisance rénale malgré l'administration de perchlorate de potassium.
Cela a été trouvé dans 8 sur 21 etudes de malades sous traitement
conservateur medical dans 35 sur 41 etudes de malades en hémodialyse,
dans 12 sur 22 etudes de receveurs de transplant renal, et dans 1 étude
sur 5 malades atteint d'insuffisance rénale aigue, mais non chez 33
personnes indemnes de maladie rénale. Une retention anormale du
pertechnetate a egalement été observée dans les glandes salivaires de 21
parmi les malades rénaux. L'augmentation de Ia localisation du pertech-
netate de 99"Tc ne pouvait pas être reliée aux concentrations sanguines
de radioactivité élevées, a une alteration de Ia liaison protéique, a une
augmentation du marquage érythrocytaire, ni a un trouble de l'absorp-
tion gastrointestinale de perchlorate de potassium. II est propose que ce
résultat représente une manifestation de dysfonctionnement des plexus
choroIdes, resultant d'une alteration de Ia conservation des anions par
cet organe. Une relation possible avec l'atteinte neurologique de
l'insuffisance rénale chronique est suggeree.
The choroid plexus, site of cerebrospinal fluid production,
actively concentrates ssmTc pertechnetate, a material often
used in the performance of brain scintigraphy [1]. To avoid the
interference of pertechnetate localization with the interpreta-
tion of brain scans, potassium perchlorate is given routinely to
persons undergoing this examination.
Following the casual observation of visualization of the
choroid plexus on pertechnetate brain scans in several patients
with endstage renal disease, we undertook a systematic study to
determine the frequency of this finding and its possible causes.
drugs were administered within 15 mm of each other. Imaging
was accomplished with a dual probe nuclear rectilinear scanner
(Model 084 Ohio, Technicare Corporation, Cleveland, Ohio).
Eighty-four brain scans were performed in 70 patients with
chronic renal insufficiency, which included 21 studies of pa-
tients receiving conservative medical treatment, 41 of patients
on chronic hemodialysis, and 22 of renal transplant recipients.
For comparison, we also reviewed brain scans performed on 33
patients referred for various neurological problems. Each one
of these patients immediately followed or preceded a chronic
renal patient on the day's schedule and formed the "control"
group. During a later period, brain scans were performed on
five persons with acute renal insufficiency.
Scans were reviewed by two observers, one of whom was
unaware of the patient's clinical condition. The presence of
visualization of the choroid plexus was noted and classified as
slight (+), moderate (+ +), or marked (+ + +). Notation was
also made as to whether or not the parotid glands, which may
also concentrate this material, were clearly visible in these
studies.
In five renal patients in whom the choroid plexus was
visualized despite medication with perchiorate, the study was
repeated following oral administration of strong iodine solution,
0.5 ml, US Pharmacopeia, Rockville, Maryland. Iodide is also
usually effective in blocking the uptake of pertechnetate by the
choroid plexus. Eight renal patients with elevated serum creati-
nine had brain scans following the administration of s9mTc
diethylenetriaminepenta-acetic acid (DTPA). This complex is
commonly used for brain scanning to avoid localization of
radioactive technetium in the choroid plexus.
To determine if labelling of erythrocytes or altered plasma
protein binding with mTc could play a role in the visualization
of the choroid plexus we performed the following experiments:
In ten patients including six of the chronic renal group and
four controls, blood samples were secured 30 mm after the
administration of pertechnetate (99mTc) for determination of in
vivo labelling of erythrocytes. Erythrocytes were separated by
centrifugation and washed with normal saline. The proportion
of activity per unit of volume of whole blood, erythrocytes, and
plasma was determined.
Methods
Brain scans were performed 1 to 2 hr following the adminis-
tration of 20 to 30 mCi of 9smTc pertechnetate by the intrave-
nous route and 300 mg of potassium perchlorate orally. The two
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In nine renal patients on maintenance hemodialysis and ten
normal persons, the in vitro association of ssmTc pertechnetate
with serum proteins was examined by the equilibrium dialysis
method described by Hays and Green [21.
A possible role of blood radioactivity levels in choroid plexus
visualization was tested in the following two observations:
In 20 unselected subjects, including patients with acute and
chronic renal insufficiency and nonrenal patients, the whole
blood concentration of ssmTc radioactivity was determined at
the time of starting the brain scan, and it was related to the
degree of visualization of the choroid plexus.
In three patients with chronic renal insufficiency requiring
hemodialysis the level of blood radioactivity was determined 1
hr after injection, immediately preceding brain scanning. He-
modialysis was then carried out for 4 hr at the end of which
blood radioactivity determination and brain imaging were
repeated.
To view the distribution of activity in the salivary and thyroid
glands and the large vessels at the base of the neck, scintillation
camera views were taken 30 to 180 mm after the injection of
99mTc pertechnetate in six renal patients and seven controls.
Potassium perchlorate was taken by these patients immediately
after the 30-mm scintiphoto had been obtained. One of them
was given lemon and later a full meal, and viewing was repeated
after 5 hr.
To test the possibility that impaired absorption of perchlorate
might explain the results observed, the gastrointestinal absorp-
tion of sodium s9mTc pertechnetate, a very similar ion, was
studied. Five normal adults and five patients with chronic renal
failure requiring hemodialysis were given 2 mCi per 70 kg body
weight of sodium s9mTc pertechnetate orally at least 2 hr after
the last meal. Heparinized blood samples were secured 30, 60,
and 120 mm afterward. The radioactivity of each whole blood
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Fig. 2. Frequency and degree (LII, none; ii, small; 1111, moderate to
marked) of choroid plexus visualization on brain scan in patients with
chronic renal disease. The majority (38 of 48) of those whose serum
creatinine was >3 mg/dl showed abnormal concentration. Twelve
patients with abnormal localization and serum creatinine <2 were
recipients of renal transplants. In this group the finding could not be
related to the level of creatinine (Table 1).
sample (cpm/mlIM2 of body surface corrected to 0 time) was
determined in duplicate in a well scintillation counter.
Results
Figure I summarizes the results of brain scans in each group.
Fifty-six brain scans in renal patients including subjects in each
treatment category showed a concentration of pertechnetate in
the choroid plexus, although this was not seen in any of the
control group. The finding was by far most pronounced and
frequent in patients on hemodialysis.
The frequency of visualization of the choroid plexus correlat-
ed with the level of serum creatinine which may be considered
an index of severity or duration of disease (Fig. 2). Patients
whose serum creatinine was above 3 mg/dl (38 of 48) usually
concentrated pertechnetate in the choroid plexus, but the
majority of those with serum creatinine below that level did not.
The exception was 12 transplant recipients whose creatinine
level was normal or slightly elevated at the time of examination.
In this group the serum level of creatinine was 1.5 0.5 mg/dl
among those in whom the choroid plexus was seen and 1.8
1.1 mg/dl among those in whom it was not visualized (Table 1).
Also to be noted is that only one of five patients with acute renal
failure (serum creatinine 4 to 10 mg/dl) had this finding.
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Fig. 1. Frequency and degree of choroid plexus visualization on brain
scan in patients with chronic renal insufficiency according to treatment
modality, acute renal failure, and nonrenal. Symbols relating to cho-
roid plexus visualization are: LI, none; , small; ll, moderate to
marked.
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Fig. 3. Brain scan of patient with chronic renal insufficiency. A Lateral
view, 1 hr after administration of 99"Tc pertechnetate and potassium
perchiorate. Whole blood radioactivity, 36,500 CPM/ml. B Posterior
and lateral views after 4 hr of hemodialysis (7 hr after s9mTc pert echne-
tate). Whole blood radioactivity was 12,600 CPM/ml.
Choroid plexus visualized 6
Abbreviation: N, number of transplant recipients.
a Difference is not statistically significant.
A relation could not be established between plasma radioac-
tivity and visualization of the choroid plexus in the 20 patients
in which this observation was recorded (Table 2). Neither was
this apparent in the three patients where reduction of blood
1 8 + 11 activity resulted from hemodialysis. In these patients the cho-—
roid plexus was visualized just as clearly when the lower blood
1.5 0.5 radioactivity level was obtained as it was initially (Fig. 3).
The choroid plexus was visualized in all five patients given
the strong iodine solution. These patients had also previously
shown abnormal uptake when perchiorate was given. None of
the eight renal patients given s9mTc DTPA showed concentra-
tion in the choroid plexus.
The activity ratio between erythrocytes and plasma in ten
patients did not differ significantly between the renal (0.28
0.11) and control groups (0.34 0.11; Table 3). The values
obtained are similar to those reported by others [21.
The association of ssmTc pertechnetate with serum proteins
examined by equilibrium dialysis in patients with renal insuffi-
ciency and normal persons is summarized in Table 4. The
values obtained in the normal persons were similar to those also
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Table 1. Serum creatinine and choroid plexus visualization in
transplant recipients
Choroid plexus not visualized 8
N
Serum creatinine,
mg/dla
Table 2. Blood radioactivity related to choroid plexus visualization
N Range' Mean SD'
Choroid plexus not visualized 13 9 to 183 130 73.8
Visualized 7 48 to 250 92 46.8
Abbreviation: N, number of patients.
a Net counts per minute x 103/ml whole blood.
The difference between the two groups is not statistically
significant.
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reported by Hays and Green [2]. Lower values for protein
binding, which relates to hypoalbuminemia found in several
subjects, were found in the renal patients.
Review of all the brain scans on renal patients and controls
with potassium perchlorate premedication also revealed persist-
ent activity in the salivary glands in 16 patients with renal
insufficiency and in five controls. Fourteen of the 16 renal
patients also showed localization in the choroid plexus.
We looked specifically in four of the six renal patients for
localization of pertechnetate in the salivary and thyroid glands;
persistent localization up to 3 hr was observed (Fig. 4). In one
patient salivary gland activity was not discharged after stimula-
tion with lemon juice and a full meal. In each of the four patients
the choroid plexus showed considerable activity 1 hr after
administration of 99mTc pertechnetate. In all control patients
pertechnetate was discharged by the salivary and thyroid glands
following the administration of potassium perchiorate.
The level of radioactivity in the blood after oral administra-
tion of ssmTc pertechnetate in normal persons and renal patients
was similar at each interval tested.
The mean and 1 SD of blood radioactivity for five normal and
five renal patients, respectively, at each time interval tested
was as follows: 5.92 x l0 2.61 x ICS and 7.67 x io 2.3 x
l0 at 30 mm; 6.29 x l0 1.1 x l0 and 6.73 x i05 2.16 x
l0 at 60 mm; 5.83 x lO 8.30 x 10 and 5.56 x 10 1.85 x
l0 at 120 mm. The differences between normal and renal
patients are not statistically significant (X2) (Fig. 5).
Localization of pertechnetate in the choroid plexus of renal
patients was detected in the presence of various diseases,
including polycystic kidney disease. All patients examined who
exhibited neuropsychiatric syndromes had this finding, but so
did many who had no obvious neurological problems.
Discussion
We have observed that, despite the administration of perchlo-
rate or iodide, the choroid plexus is visualized frequently on
Tc pertechnetate brain scan in patients with chronic renal
failure but generally not in patients with acute renal insufficien-
cy. This finding is unusual under normal conditions, particular-
ly the marked localization that permitted visualization of the
extension of the plexus into the fourth ventricle in many
patients [1, 3—5].
The increased concentration of pertechnetate in the choroid
plexus may be interpreted as an alteration in the function of this
organ, consisting of augmented transport of this ion into the
lining epithelium or its decreased ability to transfer the material
into the cerebrospinal fluid or back into the blood [41.
The possibility that increased choroid plexus localization of
pertechnetate is the result of high blood concentration resulting
Renal insufficiency 9 68.2 7.6
Abbreviation: N, number of patients.
Difference is statistically significant (P > 0.001).
from decreased renal excretion was considered, but seems
unlikely for several reasons. The fact that the finding was
inconstant in persons with renal insufficiency suggests the
contribution of other factors. Higher blood concentrations of
perchlorate, a very similar ion, may well also occur in these
patients, augmenting its inhibitory effect on pertechnetate ex-
traction. Also contrary to this explanation is the observation
that correction of renal insufficiency by renal transplantation
does not appear to alter the finding. The infrequency of this
finding in patients with acute renal insufficiency and its persis-
tence after the reduction of blood radioactivity levels by
hemodialysis thus cannot be explained. Neither does in vivo
labelling of erythrocytes appear to be a factor. In some cases,
the data presented may support the alternate possibility of
reduced avidity of pertechnetate for serum albumin which
might facilitate its localization in the plexus.
A reduced effect of perchlorate on the transfer of pertechne-
tate into the choroid plexus resulting from impaired gastrointes-
tinal absorption may be considered but appears unlikely. Gen-
eralized malabsorption is not prevalent among patients with
renal insufficiency [61. None of the patients studied presented
with clinical evidence of gastrointestinal disease. Our finding of
normal absorption of pertechnetate, an ion very similar to
perchlorate, also weighs against this possibility.
It should not be surprising that 99mTc DTPA did not behave
similarly to 99mTc pertechnetate considering its different molec-
ular configuration and size. The handling of this complex by the
choroid plexus is likely to be different. Incidentally, we suspect
that the widespread use of this complex in brain scanning may
be a reason why this abnormality has not been observed by
others.
The salivary and thyroid glands as well as the choroid plexus
possess transport mechanisms capable of extracting various
anions from the blood. Following intravenous administration,
s9mTc pertechnetate promptly localizes in the salivary and
thyroid glands. Maximal concentration is reached in the thyroid
in approximately 30 mm [7, 81. The administration of perchlo-
rate normally produces prompt release of pertechnetate from
both glands.
The finding of persistent localization of pertechnetate in the
salivary and thyroid glands in the patients who also retained it
in the choroid plexus suggests a widespread abnormality in the
handling of this ion by cellular elements. This distribution is
similar, but not identical, to that reported by Aneri, Loug-
champt, and Bassett [9] in patients receiving stannous citrate or
pyrophosphate prior to the administration of pertechnetate.
One may postulate that retention of tin or other substances
related to renal failure could be the cause. These could lead to
changes in the cellular macromolecules.
Table 3. Distribution of ssmTc pertechnetate in blood
CP
N RBC/Plasmaa visualization
Control 4 0.34 0.11 0
Renal 6 0.28 0.11 4
Table 4. Binding of 99mTC pertechnetate to atbumin
Abbreviations: CP, choroid plexus; N, number of patients.
a Difference is not statistically significant.
N % bound
Serum albumin
gidi
Normal 10 83.3 l.3 5.7 0.3
3.6 0.6
C
E0
c)
C
E0
Control
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Fig. 4. 99'"Tc pertechnetate localization in the salivary and thyroid glands 30 mm after administration (upper) and 180 mm after the addition of
potassium perchlorate (lower), in a patient with normal renal function and in one with chronic renal insufficiency. Persistent localization in the
salivary and thyroid glands is evident in the latter. Arrows point to the thyroid and salivary glands.
Grantham [101 described alterations in the transport of fluid
and organic ions by renal tubules and altered cerebrospinal fluid
caused by uremic sera. He relates this to aryl acids, substances
which are actively transported by the choroid plexus, the
thyroid, and the kidney.
The fact that the abnormality is found in patients with
polycystic kidneys as well as in other renal diseases argues
against a possible immunological mechanism. Persistence of
these findings after adequate renal function has been restored
by transplantation appears to indicate remaining cellular dam-
age or failure of its cause to be removed by this procedure.
We considered the possible clinical implication of our find-
ings. Physiological studies [11, 12] in our opinion have thor-
oughly documented the role of choroid plexus function and
cerebrospinal fluid circulation and in the metabolic homeostasis
of the central nervous system. Alterations in choroid plexus
function have been related to the neurological pictures accruing
in plexus papilloma [131, hydrocephalus [14], African trypano-
somiasis [151, lupus erythematosus [16], Goodpasture syn-
drome [17], and immune complex disease [18].
Neuropsychiatric disorders are among the most frequent and
serious complications of chronic renal disease. The pathogene-
sis of many of these disorders is poorly understood. Cerebral
scintigraphy in some patients has revealed specific abnormali-
ties such as chronic subdural hematoma, venous sinus thrombo-
sis, cerebral infarction, or abscess. In other patients nonspecific
alterations have been observed and attributed to cerebral
edema [191 or to the binding of pertechnetate to erythrocytes in
the presence of abnormal concentration of tin [9]. In most
patients, however, the brain scan is normal.
Radionuclide cisternography has revealed abnormal cerebro-
spinal fluid dynamics in some patients with dialysis dementia
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Fig. 5. Blood radioactivity following oral administration of sodium
"Tc pertechnetate in five patients with chronic renal failure
(0—) and five normals (0 ) (mean and 1 SD). The levels attained
by the two groups at each interval are similar indicative of an absence of
malabsorption in the renal patients.
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[20]. If the abnormality in the handling of pertechnetate by the
choroid plexus described in this study is a sign of dysfunction of
this organ which may also affect physiologically important
substances, then these two findings lend support to the previous
suggestion by Grantham [10] linking abnormality in cerebrospi-
nal fluid secretion to the pathogenesis of neurological syn-
dromes in patients with renal insufficiency. Longitudinal stud-
ies are needed to determine the time sequence of onset of these
findings and their possible relation to the neurological
syndromes.
study.
